Top Analyst Reports for AbbVie, RTX & IBM
View original at finance.yahoo.comTop Analyst Reports for AbbVie, RTX & IBM Tuesday, February 17, 2026 The Zacks Research Daily presents the best research output of our analyst team…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
IBM's acquisition spree has escalated integration risks, while its high debt level is burdensome
80% confidenceCheck Point is gaining from solid contributions of its growth-oriented products, primarily CloudGuard, Sandblast Zero-day threat prevention and Infinity solutions
80% confidenceBoise Cascade is hurting due to slow single-family housing starts, resulting in low volumes and unfavorable commodity pricing
80% confidenceSupply-chain challenges continue to affect the aerospace sector, which may adversely impact RTX
80% confidenceIBM's focus on quantum technology for solutions to complex problems beyond the reach of classical computing is a tailwind
80% confidenceStrength in hybrid cloud, AI-powered automation, and enterprise consulting is driving growth in IBM's Software and Consulting segment
80% confidenceAbbVie has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq
80% confidenceIBM is gaining traction on the Watsonx platform, which is likely to be its core technology platform for AI capabilities
80% confidenceAbbVie faces several headwinds like Humira LOE impact, slowing oncology sales and continued macro headwinds for Aesthetics
80% confidenceDaVita's patient-centric care model leverages its platform and continued execution of targeted initiatives to improve treatment adherence is an added plus
80% confidenceAbbVie has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline that should drive long-term growth
80% confidenceRTX continues to receive ample orders for its wide range of combat-proven defense products from the Pentagon and its foreign allies
80% confidenceEVI delivered solid top-line momentum, with revenues rising 24% in the December quarter and 20% for the first six months of FY26, alongside gross margin expansion to ~31%
80% confidenceThe uncertainties created by the recent imposition of U.S. government-issued import tariffs pose a risk for RTX
80% confidenceCorcept's sole dependence on Cushing's syndrome drug, Korlym, for revenues is concerning
80% confidenceEasing demand momentum amid persistent headwinds hurts Shake Shack with limited traffic growth, inflation pressures and weather disruptions remaining a concern
80% confidenceEVI's fiscal 2025 acquisitions contributed $40 million in revenues and $2 million in net income year to date
80% confidenceImproved mix, pricing discipline and operating leverage are enhancing EVI's earnings quality
80% confidenceEVI's earnings conversion remains pressured with net income dipping to $4.2 million as SG&A rose 26%, outpacing revenue growth
80% confidenceEVI's operating cash flow improved to $5.1 million despite a $12.6 million inventory build
80% confidenceGrowth in Affirm's active merchant numbers and improvement in Gross Merchandise Value will fuel its top-line
80% confidenceAbbVie's neuroscience portfolio is contributing to top-line growth
80% confidenceRocky Mountain is working on margin-first execution which is driving structural recovery with manufacturing gross margin rising to 21.4% from 10%
80% confidenceSteadily improving global commercial air traffic boosts RTX's sales
80% confidenceStrong volumes and a favorable mix across large commercial engines and Pratt Canada operations are expected to support RTX's growth momentum in the commercial aerospace market
80% confidenceSkyrizi and Rinvoq are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years
80% confidenceRising expenses remain a concern for Affirm
80% confidenceRocky Mountain faces near-term liquidity and covenant risk, with $0.6 million cash, continued operating losses, high-cost 12% debt and reliance on external funding
80% confidenceStrong service and parts growth support Penske's earnings, though declining BEV units and softer premium demand may limit near-term results
80% confidenceAbbVie delivered robust net sales growth in 2025 which is just the second full year following the Humira LOE in the United States
80% confidence